Corvus Pharmaceuticals
CRVS
85 hedge funds and large institutions have $202M invested in Corvus Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 8 closing their positions.
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $10.1M
37% more funds holding
Funds holding: 62 → 85 (+23)
27% more capital invested
Capital invested by funds: $159M → $202M (+$43.3M)
10.7% more ownership
Funds ownership: 48% → 58.7% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$20M |
| 2 |
SC
Samlyn Capital
New York
|
+$16M |
| 3 |
DM
Deerfield Management
New York
|
+$7.47M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.94M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.71M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.51M |
| 4 |
Millennium Management
New York
|
-$1.17M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$724K |
CRVS Hedge Fund Activity: Q4 2024 in Review
85 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2024, worth a combined $202M — up 27% from $159M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CRVS positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 12 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $20M. The largest seller was Point72 Asset Management, cutting an estimated $18.9M.
- 85 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2024, up from 62 in Q3 2024.
- Funds reported $202M of Corvus Pharmaceuticals stock for Q4 2024, up 27% quarter-over-quarter.
- 32 funds opened new Corvus Pharmaceuticals positions in Q4 2024 and 8 closed out, a net change of +24 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2024 was RTW Investments, an estimated $20M added.
- The largest Corvus Pharmaceuticals seller in Q4 2024 was Point72 Asset Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2024.